
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
uniQure is a gene therapy company focused on developing treatments for genetic and other devastating diseases, with a strong pipeline and promising collaborations. The company has shown a focus on sustainability and growth while addressing high-cost and high-mortality diseases, which could position QURE for long-term success. However, as with any biotech company, there are inherent risks and uncertainties involved, and further clinical data and regulatory approvals are needed to fully support its potential for success.
Bears say
uniQure is heavily dependent on the success of its lead development candidate, AMT-130, for Huntington's disease, which has faced delays and setbacks in its development. Additionally, the company has a limited track record in the market, with no revenue-generating products currently. Their financials also pose risks, as they are a clinical stage company with high expenses and a reliance on grants and additional funding. The success of their pipeline and achievement of their target price is heavily dependent on the success and commercialization of AMT-130, making it a high-risk investment.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares